Narcolepsy

This study tests whether HBS-301 (pitolisant) can reduce excessive daytime sleepiness and cataplexy (sudden muscle weakness) in adults with narcolepsy. Participants receive either the drug or a placebo for several weeks, followed by an open-label phase where everyone gets the dru…

This study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking…

This early-stage study tests a new drug called VX-433 in 118 people with narcolepsy type 1. The main goal is to check if it is safe and how the body processes it. Researchers will also see how VX-433 interacts with other drugs like midazolam and bupropion. This is a first step to…

This study tests whether TAK-861 can control symptoms of narcolepsy type 1, a condition causing sudden sleep attacks and muscle weakness. About 88 adults will take TAK-861 for several months, then some will switch to a placebo to see if symptoms return. The goal is to see if the …

This study is a long-term follow-up for people with narcolepsy or idiopathic hypersomnia who previously took the experimental drug ORX750. Researchers want to see if the drug remains safe and effective over time. About 90 participants will take ORX750 orally and be monitored for …

This study is checking the long-term safety of a drug called TAK-861 in 500 people with type 1 narcolepsy who have already taken it in earlier trials. Participants will continue taking TAK-861 tablets, and researchers will monitor for side effects. The goal is to see if the drug …

This study is testing whether simple wearable devices can accurately screen for sleep disorders in children with cerebral palsy. About 140 children aged 6 to 15 will wear the devices at home and then undergo a standard hospital sleep test. The goal is to see if the wearable metho…

This study tests a new tablet called ALKS 2680 to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo for 12 weeks. The main goal is to measure how well they can stay awake using a standa…

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tes…

This study tests an experimental drug called cleminorexton in 222 adults with narcolepsy type 1 or 2. The drug mimics a natural brain protein that helps keep people awake. The goal is to see if it safely reduces daytime sleepiness and improves daily functioning. Participants must…

This study tests a new drug, TAK-360, for adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). About 92 participants will receive either TAK-360 or a placebo to see if the drug is safe and well-tolerated. Participant…

This study tests a new drug called TAK-360 for people with narcolepsy type 2, a condition that causes severe daytime sleepiness. The drug acts like a natural brain chemical (orexin) that helps keep people awake. About 88 adults will receive either TAK-360 or a placebo to see if t…

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce severe daytime sleepiness and sudden muscle weakness (cataplexy) in adults with narcolepsy type 1. About 150 participants will receive either the drug or a placebo for 12 weeks. The study measures improve…

This early-stage trial is testing a new drug called Lu AH69593 to see if it is safe and how the body handles it. The study includes healthy volunteers and people with narcolepsy. Researchers will monitor side effects and measure drug levels in the blood, including how food affect…

This study tests whether E2086, an oral tablet, can reduce excessive daytime sleepiness in adults with narcolepsy. About 64 participants will receive either the drug or a placebo for 4 weeks. Researchers will measure how long people can stay awake using a standard test, and also …

This study tests a new drug called ORX750 (cleminorexton) in 248 adults with narcolepsy type 1, type 2, or idiopathic hypersomnia—conditions that cause severe daytime sleepiness. The drug mimics a natural brain protein that helps keep people awake. The main goals are to check saf…

This study follows 1,000 adults in Canada who are authorized to use medical cannabis for pain, sleep issues, anxiety, depression, or epilepsy. Researchers will track changes in symptoms using standard questionnaires over 24 weeks. The goal is to see how well medical cannabis work…

This study is testing the long-term safety and how well ALKS 2680 works over time in people with narcolepsy type 1, type 2, or idiopathic hypersomnia. Participants take a once-daily tablet at different doses. The goal is to see if the drug remains safe and effective for staying a…

This study tests a 4-week online course designed to help adults who experience parasomnias—unwanted sleep events like sleep terrors, sleepwalking, and nightmares. The course teaches safety planning, relaxation, and therapy techniques. Researchers will measure whether it reduces h…

This study tests whether a special memory support program can help people aged 50 and older remember and stick to their sleep treatment. The program uses simple memory strategies alongside standard sleep therapy. Researchers will track sleep quality, daily functioning, and life s…

This study tests whether taking branched chain amino acids (BCAAs) twice a day for three weeks can improve sleep in people with traumatic brain injury. Researchers will also check if the supplement is easy to take and if participants stick with it. The study involves 300 veterans…

This study tests a new extended-release version of sodium oxybate taken as a single dose at bedtime for children with narcolepsy type 1. Researchers want to see if kids prefer it over current twice-nightly options and if it is safe and convenient. About 36 children from Stanford …

This study tracks pregnant women with narcolepsy who take pitolisant (Wakix) or other narcolepsy medications, as well as pregnant women without narcolepsy who take pitolisant. Researchers compare pregnancy outcomes, including birth defects, to see if the drug poses risks. The goa…

This study looks at how eating affects sleepiness and nighttime sleep in people with type 1 narcolepsy, idiopathic hypersomnia, and healthy volunteers. Over 4 days, participants will log their meals, wear a glucose monitor, and track sleep with a headband and watch. The goal is t…

This study looks at how narcolepsy (types 1 and 2) and idiopathic hypersomnia affect social cognition—skills like recognizing emotions and making decisions. Researchers will give 75 adults several questionnaires to measure attention, impulse control, empathy, and emotion recognit…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. No treatment o…

This study looks at pain in people with idiopathic REM sleep behavior disorder (iRBD), a condition that strongly increases the risk of developing Parkinson's disease. Researchers will compare pain levels and patterns between 24 participants with iRBD and a control group with narc…

This study looks at proteins and metabolites in the body fluids of 60 people with narcolepsy, a rare sleep disorder. The goal is to find biological markers that could explain what causes the condition and help doctors diagnose it more accurately. Participants provide samples for …

This study looks at how reliable the Maintenance of Wakefulness Test (MWT) is for people who feel very sleepy during the day. Researchers will test 100 participants twice to see if the results are consistent. If the test proves reliable, it could help doctors decide who is safe t…

This research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…

This study looks at whether changes in gut bacteria and increased intestinal permeability can trigger inflammation that damages brain cells in people with type 1 narcolepsy. Researchers will collect blood, stool, and spinal fluid samples from 120 participants to measure bacterial…